Total Payments
$188,611
2024 Payments
$6,273
Companies
49
Transactions
1,193
Medicare Patients
3,658
Medicare Billing
$561,937
Payment Breakdown by Category
Other$154,975 (82.2%)
Food & Beverage$23,584 (12.5%)
Travel$7,656 (4.1%)
Consulting$2,250 (1.2%)
Education$87.11 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $154,975 | 90 | 82.2% |
| Food and Beverage | $23,584 | 1,035 | 12.5% |
| Travel and Lodging | $7,656 | 59 | 4.1% |
| Consulting Fee | $2,250 | 1 | 1.2% |
| Education | $87.11 | 7 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $58,871 | 139 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $44,569 | 90 | $0 (2024) |
| Novo Nordisk Inc | $37,212 | 266 | $0 (2024) |
| Mannkind Corporation | $16,662 | 124 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $12,597 | 36 | $0 (2019) |
| Corcept Therapeutics | $4,537 | 64 | $0 (2024) |
| Senseonics, Incorporated | $3,440 | 4 | $0 (2020) |
| Lilly USA, LLC | $1,474 | 98 | $0 (2024) |
| Insulet Corporation | $1,455 | 61 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $1,004 | 29 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,273 | 95 | Mannkind Corporation ($4,050) |
| 2023 | $8,910 | 94 | MannKind Corporation ($7,052) |
| 2022 | $16,506 | 115 | Novo Nordisk Inc ($14,284) |
| 2021 | $19,717 | 143 | Novo Nordisk Inc ($10,070) |
| 2020 | $25,536 | 139 | Novo Nordisk Inc ($10,088) |
| 2019 | $26,090 | 185 | AstraZeneca Pharmaceuticals LP ($19,761) |
| 2018 | $35,620 | 216 | AstraZeneca Pharmaceuticals LP ($18,767) |
| 2017 | $49,959 | 206 | SANOFI-AVENTIS U.S. LLC ($28,493) |
All Payment Transactions
1,193 individual payment records from CMS Open Payments — Page 1 of 48
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $28.21 | General |
| 12/18/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: Endocrinology | ||||||
| 12/17/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: Diabetes | ||||||
| 12/17/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: DIABETES MEDICINE | ||||||
| 12/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $27.80 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/03/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $27.80 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/02/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/26/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: PSYCHIATRY | ||||||
| 11/21/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $51.00 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Cardio-renal | ||||||
| 11/12/2024 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $23.17 | General |
| 11/07/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG, LYNPARZA | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: DIABETES MEDICINE | ||||||
| 10/22/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 10/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/10/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: Endocrinology | ||||||
| 10/08/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $25.10 | General |
| Category: Durable Pump | ||||||
| 10/08/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: DIABETES MEDICINE | ||||||
| 10/07/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/04/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Diabetes | ||||||
| 09/30/2024 | Mannkind Corporation | AFREZZA (Drug) | Travel and Lodging | Cash or cash equivalent | $18.76 | General |
| Category: DIABETES MEDICINE | ||||||
| 09/30/2024 | Mannkind Corporation | AFREZZA (Drug) | Travel and Lodging | Cash or cash equivalent | $12.00 | General |
| Category: DIABETES MEDICINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 882 | 2,336 | $308,770 | $142,486 |
| 2022 | 14 | 833 | 1,891 | $266,107 | $130,605 |
| 2021 | 15 | 986 | 2,329 | $332,405 | $167,250 |
| 2020 | 14 | 957 | 1,715 | $274,676 | $121,596 |
Total Patients
3,658
Total Services
8,271
Medicare Billing
$561,937
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 302 | 941 | $150,590 | $78,157 | 51.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 40 | 251 | $20,080 | $8,974 | 44.7% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 40 | 249 | $24,900 | $8,736 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 59 | 127 | $21,958 | $7,996 | 36.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 73 | 110 | $13,785 | $7,409 | 53.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $12,250 | $5,323 | 43.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 35 | 89 | $11,570 | $5,255 | 45.4% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 33 | 155 | $9,300 | $4,639 | 49.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 44 | 46 | $15,112 | $4,571 | 30.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 40 | 40 | $11,809 | $3,751 | 31.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 30 | 115 | $5,750 | $3,011 | 52.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $4,800 | $1,986 | 41.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 14 | $3,085 | $1,621 | 52.6% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 53 | 67 | $2,010 | $637.84 | 31.7% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 18 | 19 | $570.00 | $264.10 | 46.3% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 38 | 48 | $1,200 | $154.08 | 12.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 319 | 899 | $143,840 | $76,903 | 53.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 58 | 154 | $20,020 | $8,366 | 41.8% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 41 | 193 | $19,300 | $7,460 | 38.7% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 41 | 196 | $15,680 | $7,212 | 46.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 63 | 70 | $17,500 | $7,025 | 40.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 46 | 46 | $11,500 | $5,617 | 48.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 56 | 77 | $9,625 | $4,743 | 49.3% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2022 | 13 | 13 | $4,420 | $2,774 | 62.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 17 | $5,100 | $2,299 | 45.1% |
About Dr. Vikramjeet Kumar, MD
Dr. Vikramjeet Kumar, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Elyria, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1841271269.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vikramjeet Kumar, MD has received a total of $188,611 in payments from pharmaceutical and medical device companies, with $6,273 received in 2024. These payments were reported across 1,193 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($154,975).
As a Medicare-enrolled provider, Kumar has provided services to 3,658 Medicare beneficiaries, totaling 8,271 services with total Medicare billing of $561,937. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Internal Medicine|Endocrinology, Diabetes & Metabolism
- Location Elyria, OH
- Active Since 11/11/2005
- Last Updated 05/01/2024
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1841271269
Products in Payments
- FARXIGA (Drug) $49,275
- SOLIQUA (Drug) $27,555
- Ozempic (Drug) $17,071
- AFREZZA (Drug) $16,662
- TOUJEO (Drug) $15,957
- INVOKANA (Drug) $12,591
- Rybelsus (Drug) $10,920
- BYDUREON (Drug) $9,558
- RYBELSUS (Drug) $7,253
- Korlym (Drug) $4,537
- Eversense (Device) $3,440
- Omnipod (Device) $1,455
- JARDIANCE (Drug) $698.68
- SOLIQUA 100/33 (Biological) $666.89
- HUMULIN (Drug) $572.95
- TEPEZZA (Biological) $544.84
- JANUVIA (Drug) $511.23
- GVOKE HYPOPEN (Drug) $489.08
- Dexcom G6 Transmitter (Medical Supply) $427.73
- V-GO (Device) $410.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.